Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of E-WE Thrombin in Healthy Adults
NCT03453060Phase 1Completed
- Sponsor
- Aronora, Inc.
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AB002 in thrombosis (5 arms), sponsored by Aronora, Inc. Primary endpoints: Treatment-emergent Adverse Events at 1 month, Clinically Significant Changes in Vital Signs at 2 days and 7 more. Started May 2018; status: completed.
02
Drugs
AB002
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03453060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453060.